Nintedanib

  • BIBF 1120
  • Intedanib (free base)
  • Methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylen}-2-oxo-2,3-dihydro-1H-indol-6-carboxylat
  • 656247-17-5 ( ethane sulfonate salt)
  • 928326-83-4 (free base)

Yellow crystalline solid

Immunosuppressant

244-251 ° C

  • Very poorly soluble in water
  • Slightly soluble in DMSO (25 g · l -1)

Attention

Template: Infobox chemical / molecular formula search available

Nintedanib is a tyrosine kinase inhibitor and angiokinase, blocks the vascular endothelial growth factor, fibroblast growth factor and platelet derived growth factor receptors. The drug inhibits the formation of new blood vessels to supply to tumors (tumor angiogenesis). Nintedanib is effective against lung cancer and pulmonary fibrosis. On October 14, 2013, the drug for European drug approval was submitted.

CAS registry number PubChem Dimethyl sulfoxide Dangerous Substances Directive (67/548/EEC) Tyrosine-kinase inhibitor Regulation of therapeutic goods Digital Object Identifier
605633
de